Resolvyx Pharmaceuticals

Resolvyx Pharmaceuticals wins $17M in first-round funding

Boston Business Journal - December 9, 2005
Biotechnology startup Resolvyx Pharmaceuticals Inc. has nailed down $17 million in first-round financing, Private Equity Week is reporting.

The Waltham company's backers include Atlas Venture, which has housed the company in its early stages, according to the report. Other investors include CHL Medical Partners and Flagship Ventures.

About Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals is a privately held biotechnology company dedicated to the development and commercialization of novel therapies to treat inflammatory diseases. The company's key technologies are based on small molecules derived from the enzymatic oxidation of omega-3 fatty acids. These small molecules, called resolvins, have been shown to have significant anti- inflammatory effects in multiple models of human disease processes. Resolvyx's drug R&D programs are focused on developing resolvin-based compounds to treat a range of both rare and highly prevalent inflammatory diseases. With its experienced management team, world-class scientists and leading investors, Resolvyx is well-positioned to capitalize on its extensive patent portfolio.

The company's headquarters are in Bedford, Massachusetts. For additional information, please visit http://www.resolvyx.com.